

Marc van de Vijver

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2579229/publications.pdf>

Version: 2024-02-01

29
papers

9,063
citations

257101

24
h-index

525886

27
g-index

29
all docs

29
docs citations

29
times ranked

14841
citing authors

#	ARTICLE	IF	CITATIONS
1	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 26, 118-145.	0.8	3,139
2	The landscape of cancer genes and mutational processes in breast cancer. <i>Nature</i> , 2012, 486, 400-404.	13.7	1,535
3	Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. <i>Nature Genetics</i> , 2011, 43, 621-629.	9.4	1,080
4	HER2 testing in gastric cancer: a practical approach. <i>Modern Pathology</i> , 2012, 25, 637-650.	2.9	478
5	Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. <i>Science</i> , 2014, 345, 1251-1243.	6.0	348
6	Lung metastasis genes couple breast tumor size and metastatic spread. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 6740-6745.	3.3	331
7	HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. <i>Modern Pathology</i> , 2014, 27, 4-18.	2.9	236
8	A Cell Proliferation Signature Is a Marker of Extremely Poor Outcome in a Subpopulation of Breast Cancer Patients. <i>Cancer Research</i> , 2005, 65, 4059-4066.	0.4	233
9	Current Perspectives on HER2 Testing: A Review of National Testing Guidelines. <i>Modern Pathology</i> , 2003, 16, 173-182.	2.9	229
10	Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. <i>Nature</i> , 2017, 543, 714-718.	13.7	229
11	Determination of Stromal Signatures in Breast Carcinoma. <i>PLoS Biology</i> , 2005, 3, e187.	2.6	180
12	Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 119-126.	1.1	142
13	Emerging Technologies for Assessing HER2 Amplification. <i>American Journal of Clinical Pathology</i> , 2009, 132, 539-548.	0.4	135
14	A Conditional Mouse Model for Malignant Mesothelioma. <i>Cancer Cell</i> , 2008, 13, 261-271.	7.7	126
15	Prevalence of serrated polyps and association with synchronous advanced neoplasia in screening colonoscopy. <i>Endoscopy</i> , 2014, 46, 219-224.	1.0	106
16	Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 631-638.	0.4	102
17	Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 101-113.	1.1	93
18	Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. <i>Breast Cancer Research</i> , 2007, 9, R68.	2.2	56

#	ARTICLE	IF	CITATIONS
19	Gene Expression Profiling and the Future of Adjuvant Therapy. <i>Oncologist</i> , 2005, 10, 30-34.	1.9	55
20	Radiation-Associated Breast Tumors Display a Distinct Gene Expression Profile. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 540-547.	0.4	55
21	HER-2 amplification is highly homogenous in gastric cancer. <i>Human Pathology</i> , 2010, 41, 304-305.	1.1	38
22	Emerging Technologies for HER2 Testing. <i>Oncology</i> , 2002, 63, 33-38.	0.9	34
23	Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 958-967.	0.4	34
24	Dilemmas for the pathologist in the oncologic assessment of pancreatoduodenectomy specimens. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 533-543.	1.4	32
25	Improving patient care through molecular diagnostics. <i>Seminars in Oncology</i> , 2004, 31, 14-20.	0.8	27
26	A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. <i>Cancer Research</i> , 2019, 79, 4315-4323.	0.4	9
27	Estrogen Receptor Phenotypes Defined by Gene Expression Profiling. <i>Cancer Treatment and Research</i> , 2009, 147, 1-18.	0.2	1
28	Current and future pathological examination in breast cancer. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 121-130.	2.2	0
29	Clinical Genomics in Oncology. , 2008, , 209-229.		0